Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein

Chung, Jae-Wook; Kim, Hyun Tae; Ha, Yun‐Sok; Lee, Eun Hye; Chun, So Young; Lee, Chan-Hyeong; Byeon, Kyeong-Hyeon; Choi, Seock Hwan; Lee, Jun Nyung; Kim, Bum Soo; Kim, Tae‐Hwan; Yoo, Eun Sang; Yoon, Ghil Suk; Baek, Moon‐Chang; Kwon, Tae Gyun

doi:10.1371/journal.pone.0250254

Cited by 8 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study showed that FABP5 distinguished between healthy individuals and patients with low-risk (GS 6) and intermediate–high-risk PCa tumours [ 193 ]. The EV levels of PTEN [ 194 ], flotillin 2 and PARK7 [ 195 ], ephrinA2 [ 196 ], Del-1 [ 197 ], the integrins ITGA3 and ITGB1 [ 198 ] and GGT1 activity [ 199 ] have also been reported to differentiate between PCa patients and healthy individuals and/or BPH patients. In addition, the prostate-enriched protein STEAP1 was found to be increased in plasma samples of PCa patients compared with healthy males [ 200 ].…”

Section: Ev-based Biomarkers For Prostate Cancermentioning

confidence: 99%

Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research

et al. 2021

View full text Add to dashboard Cite

Prostate cancer is a global cancer burden and considerable effort has been made through the years to identify biomarkers for the disease. Approximately a decade ago, the potential of analysing extracellular vesicles in liquid biopsies started to be envisaged. This was the beginning of a new exciting area of research investigating the rich molecular treasure found in extracellular vesicles to identify biomarkers for a variety of diseases. Vesicles released from prostate cancer cells and cells of the tumour microenvironment carry molecular information about the disease that can be analysed in several biological fluids. Numerous studies document the interest of researchers in this field of research. However, methodological issues such as the isolation of vesicles have been challenging. Remarkably, novel technologies, including those based on nanotechnology, show promise for the further development and clinical use of extracellular vesicles as liquid biomarkers. Development of biomarkers is a long and complicated process, and there are still not many biomarkers based on extracellular vesicles in clinical use. However, the knowledge acquired during the last decade constitutes a solid basis for the future development of liquid biopsy tests for prostate cancer. These are urgently needed to bring prostate cancer treatment to the next level in precision medicine.

show abstract

Section: Ev-based Biomarkers For Prostate Cancermentioning

confidence: 99%

Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite a lower incidence rate among Asians compared to Americans and Europeans ( 1 ), the mortality and morbidity rates associated with PCa are on the rise in China due to improvements in living standards, lifestyle changes, and advancements in screening methods ( 2 , 3 ). The use of prostate-specific antigen (PSA) for population screening, diagnosis, and monitoring of PCa has been a subject of controversy since its purification ( 4 ). Although PSA screening has some benefits, such as early detection of PCa, it also has several drawbacks, such as high costs, long waiting times, limited sensitivity, and low specificity.…”

Section: Introductionmentioning

confidence: 99%

Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer

Sun,

Tian,

Wang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundRecently, serum sialic acid (SA) has emerged as a distinct prognostic marker for prostate cancer (PCa) and bone metastases, warranting differential treatment and prognosis for low-volume (LVD) and high-volume disease (HVD). In clinical settings, evaluating bone metastases can prove advantageous.ObjectivesWe aimed to establish the correlation between SA and both bone metastasis and HVD in newly diagnosed PCa patients.MethodsWe conducted a retrospective analysis of 1202 patients who received a new diagnosis of PCa between November 2014 and February 2021. We compared pretreatment SA levels across multiple groups and investigated the associations between SA levels and the clinical parameters of patients. Additionally, we compared the differences between HVD and LVD. We utilized several statistical methods, including the non-parametric Mann-Whitney U test, Spearman correlation, receiver operating characteristic (ROC) curve analysis, and logistic regression.ResultsThe results indicate that SA may serve as a predictor of bone metastasis in patients with HVD. ROC curve analysis revealed a cut-off value of 56.15 mg/dL with an area under the curve of 0.767 (95% CI: 0.703-0.832, P < 0.001) for bone metastasis versus without bone metastasis and a cut-off value of 65.80 mg/dL with an area under the curve of 0.766 (95% CI: 0.644-0.888, P = 0.003) for HVD versus LVD. Notably, PCa patients with bone metastases exhibited significantly higher SA levels than those without bone metastases, and HVD patients had higher SA levels than LVD patients. In comparison to the non-metastatic and LVD cohorts, the cohort with HVD exhibited higher levels of alkaline phosphatase (AKP) (median, 122.00 U/L), fibrinogen (FIB) (median, 3.63 g/L), and prostate-specific antigen (PSA) (median, 215.70 ng/mL), as well as higher Gleason scores (> 7). Multivariate logistic regression analysis demonstrated that an SA level of > 56.15 mg/dL was independently associated with the presence of bone metastases in PCa patients (OR = 2.966, P = 0.018), while an SA level of > 65.80 mg/dL was independently associated with HVD (OR = 1.194, P = 0.048).ConclusionThe pretreatment serum SA level is positively correlated with the presence of bone metastases.

show abstract

“…Studies have illuminated significant variances in the approach toward the evaluation and management of hematuria among male and female patients. Efforts are currently underway to standardize evaluation processes and develop comprehensive risk stratification models, with the goal of providing equitable, unbiased, and evidence-based care to all patients, irrespective of gender [ 8 , 9 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Challenges and Management of Acquired Hemophilia A Presenting as Gross Hematuria: A Case Report

Kaltsas,

Zachariou,

Kratiras

et al. 2023

Cureus

View full text Add to dashboard Cite

Acquired hemophilia A (AHA) is a rare autoimmune disorder marked by autoantibodies against coagulation factor VIII, leading to bleeding complications. This case report explores a unique presentation of AHA, initially manifested as gross hematuria, a symptom often encountered in healthcare settings with a broad range of differential diagnoses. The background of this study highlights the rarity of AHA and its diverse clinical presentations. The case involves a 62-year-old man with no history of bleeding disorders, presenting with gross hematuria and later developing severe anemia and ecchymoses. Methods employed in the evaluation included urological assessments such as cystoscopy and computed tomography, alongside hematological investigations, which later revealed a prolonged activated partial thromboplastin time (aPTT) and a critically low factor VIII level, indicative of AHA. Results showed a lack of early recognition of coagulation abnormalities, underscoring the need for comprehensive initial assessments in cases of unexplained hematuria. The patient's management at a specialized Hemophilia Center involved inhibitor eradication therapy and management of acute bleeding episodes, resulting in significant clinical improvement. The conclusions drawn from this case emphasize the importance of considering rare conditions like AHA in the differential diagnosis of hematuria and the necessity for a broad diagnostic approach. It advocates for heightened awareness and early coagulation studies in unexplained cases of hematuria to prevent delayed diagnoses and improve patient outcomes. This case contributes to the understanding of AHA's clinical variability and the critical nature of early and comprehensive diagnostic approaches in hematuria evaluation.

show abstract

Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein

Cited by 8 publications

References 37 publications

Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research

Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research

Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer

Diagnostic Challenges and Management of Acquired Hemophilia A Presenting as Gross Hematuria: A Case Report

Contact Info

Product

Resources

About